West Paces Advisors Inc. Incyte Corp Transaction History

West Paces Advisors Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Dec 18, 2023	SELL	$66.18 - $83.18 $6,220 - $7,818	-94 Closed	0 $0
Q1 2022 Dec 18, 2023	BUY	$66.02 - $79.71 $6,205 - $7,492	94 New	94 $7.47 Million
Q2 2021 Dec 19, 2023	SELL	$79.87 - $87.53 $30,989 - $33,961	-388 Closed	0 $0
Q2 2020 Dec 19, 2023	BUY	$74.18 - $108.93 $28,781 - $42,264	388 New	388 $40.3 Million
Q1 2020 Dec 20, 2023	BUY	$63.18 - $85.97 $3,222 - $4,384	51 Added 15.13%	388 $28.4 Million
Q2 2019 Dec 21, 2023	SELL	$73.52 - $88.7 $514 - $620	-7 Reduced 2.08%	330 $28 Million
Q3 2018 Dec 20, 2023	BUY	$61.75 - $74.23 $20,809 - $25,015	337 New	337 $23.3 Million
Q2 2018 Dec 21, 2023	BUY	$60.85 - $83.98 $425 - $587	7 Added 2.12%	337 $22.6 Million
Q1 2018 Dec 21, 2023	SELL	$83.06 - $100.98 $25,748 - $31,303	-310 Reduced 48.44%	330 $27.5 Million
Q4 2017 Dec 21, 2023	BUY	$93.56 - $116.6 $5,145 - $6,413	55 Added 9.4%	640 $60.6 Million
Q3 2017 Dec 21, 2023	BUY	$109.15 - $138.27 $27,833 - $35,258	255 Added 77.27%	585 $68.3 Million
Q4 2016 Dec 21, 2023	BUY	N/A	330	330 $33.1 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of West Paces Advisors Inc., based on Form 13F filings with the SEC.

Stay updated on West Paces Advisors Inc. with notifications on news.